Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12346305 | 0.90 | KDR (0.50) | KDRPDGFRBTEKMEN1KMT2A | |
| SCHEMBL2238439 | 0.88 | PDGFRB (0.49) | KDRPDGFRBTEKMEN1KMT2A | |
| SCHEMBL2237867 | 0.87 | PDGFRB (0.48) | KDRPDGFRBMEN1KMT2ANPC1 | |
| SCHEMBL57891 | 0.85 | KDR (0.55) | KDRPDGFRBCA12CA1CA2 | |
| SCHEMBL57825 | 0.85 | KDR (0.61) | KDRPDGFRBTEKCA12CA1 | |
| SCHEMBL31212719 | 0.85 | KDR (0.61) | KDRPDGFRBTEKCA12CA1 | |
| SCHEMBL58603 | 0.84 | KDR (0.49) | KDRPDGFRBMEN1KMT2ANPC1 | |
| SCHEMBL59016 | 0.83 | KDR (0.53) | KDRPDGFRBCA12CA1CA2 | |
| SCHEMBL59878 | 0.83 | KDR (0.53) | KDRPDGFRBCA12CA1CA2 | |
| SCHEMBL3666256 | 0.83 | SMN1; SMN2 (0.59) | KDRPDGFRBMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901152-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8242139-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2452937-A1 | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | Abbott Laboratories (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2142521-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008134693-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | disclosed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | IDO1, RB1, IDO2 | KDR 1690/4885PDGFRB 1177/4885TEK 2638/4885 |
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | KDR 4482/4885PDGFRB 3184/4885TEK 1985/4885 |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | KDR 4482/4885PDGFRB 3184/4885TEK 1985/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885PDGFRB 1523/4885TEK 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.